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Objective: Several combinations of risk factors for death or cardiac events
after coronary artery bypass grafting have been described. We studied the
prognostic value of the preoperative serum levels of cardiac troponin T.
Methods: We studied 468 patients who underwent elective coronary artery
bypass grafting. Preoperative and postoperative levels of cardiac troponin
T and creatine kinase MB, electrocardiograms, clinical data, and events
were recorded prospectively. No acute ischemic changes were present on the
electrocardiogram before the operations, and preoperative creatine kinase
MB serum levels were within normal limits in all patients. Results:
Ninety-seven (97/468, 21%) patients had serum levels of troponin T greater
than 0.02 mg/L within 24 hours before coronary artery bypass grafting.
Hospital mortality was similar in this group and in the patients with
preoperative levels less than 0.02 mg/L (1% in each group). Nine patients
(9/97, 9%) with elevated levels of troponin T before the operation had a
perioperative myocardial infarction compared with 12 patients (12/371, 3%)
among the group with lower troponin T levels (p 5 0.015, RR 5 2.9).
Congestive heart failure occurred in 10 (10/97, 10%) and 8 (8/371,2%)
patients, respectively (p 5 0.0009, RR 5 4.8). Intensive care unit (p 5
0.002) and postoperative hospital length of stay (p 5 0.09) were all longer
in patients with the elevated preoperative troponin T level. In a logistic
regression analysis, troponin T level before the operation was the variable
most strongly correlated with postoperative myocardial infarction (p 5
0.003). Conclusion: Preoperative troponin T stratification before coronary
artery bypass grafting identifies a subgroup of patients with increased risk
of postoperative cardiac complications. (J Thorac Cardiovasc Surg 1998;
115:1328-34)
Several models assessing cardiac events andmortality after coronary artery bypass grafting
(CABG) were developed to predict outcome after
surgery and to measure variations in the quality of
care.1-3 Although these models give consistent
predictions, statistical computation remains diffi-
cult at the patient’s bedside. In addition, patients
are now referred for coronary surgery at a far
more advanced stage of the disease and thus
present a greater risk.4 Therefore it remains dif-
ficult to predict cardiac events after CABG oper-
ations based on preoperative clinical and angio-
graphic criteria.
Cardiac-specific troponin proteins are highly sen-
sitive markers of myocardial necrosis.5 The subunit
troponin T is specific for myocardial tissue. It is not
present in the serum of healthy volunteers and has
been successfully used for risk stratification in acute
myocardial ischemia.6 In the present study, the
relative risk of cardiac events after elective CABG
has been assessed with the use of the preoperative
troponin T serum levels, assuming that patients with
detectable troponin T levels before the operation
were at higher risk of cardiac events after the
operation. The presence of circulating troponin T in
patients undergoing elective CABG is probably the
result of unrecognized ongoing damage to the myo-
cardium.
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Patients and methods
From 1992 to 1995, 468 patients who underwent elec-
tive CABG at the Montreal Heart Institute were prospec-
tively studied to evaluate myocardial protection with
intermittent warm versus cold blood cardioplegia7 or with
antegrade versus retrograde administration of blood car-
dioplegia.8 All patients gave informed consent, and the
study protocols were approved by the Institutional Review
Board of the Montreal Heart Institute.
Patients with any of the following criteria were ex-
cluded: (1) operation within 7 days of an acute myocardial
infarction (MI); (2) emergency operation for acute coro-
nary occlusion at angioplasty; (3) emergency surgical
procedures performed outside of normal working hours;
(4) CABG operations associated with any other cardiac
surgical procedure; (5) age older than 75 years; and (6)
preoperative renal dysfunction (creatinine serum level .
200 mmol/L).
Surgical technique and myocardial protection. Opera-
tions were performed with the use of internal thoracic
artery and saphenous vein grafts in all patients. The
cardioplegic solution was infused through a 14F double-
lumen needle (Medtronic Inc., Grand Rapids, Mich.) in
the ascending aorta or through a self-inflating balloon
retrograde catheter through the coronary sinus (14F self-
inflating balloon; Research Medical Inc., Midvale, Utah).
The cardioplegia infusion set (CardioMed Supplies Inc.,
Gormley, Ontario, Canada) consisted of two inflow lines
for mixing of the crystalloid solution with blood from the
arterial circuit at a ratio of 4:1.
After the ascending aorta was crossclamped, cardiople-
gic arrest was achieved in all patients by antegrade
coronary infusion of 300 ml of high-potassium solution
over a period of 3 to 5 minutes, at a perfusion pressure not
exceeding 250 mm Hg in the infusion line, and at the same
temperature as the cardiopulmonary bypass (CPB) per-
fusate (33° C, warm cardioplegia). Diastolic arrest was
usually obtained before termination of the initial infusion.
Thereafter and for the remainder of the procedure,
intermittent bolus infusions of 200 to 300 ml of low-
potassium solution were administered antegradely in the
ascending aorta or retrogradely through the coronary
sinus after each distal anastomosis.
Markers of myocardial ischemia and diagnosis of peri-
operative MI. Blood samples for determination of the
serum levels of total creatine kinase (CK), catalytic activ-
ity of its MB isoenzyme (CK-MB), and troponin T levels
were taken before the beginning of the operation and 1
hour, 3, 6, 12, 24, and 48 hours after chest closure.
Electrocardiographic tracings were obtained the day be-
fore the operation, on arrival in the intensive care unit,
and on postoperative days 1, 2, and 3. The diagnosis of
perioperative MI was based on the presence of two of the
following criteria: (1) new Q wave or disappearance of R
wave on the postoperative electrocardiographic tracing;
(2) serum CK-MB activity concentration higher than 100
IU/L 12 to 24 hours after the operation; and (3) a positive
myocardial pyrophosphate scan.9 The latter was per-
formed only in the presence of an abnormal CK-MB
increase without changes on the electrocardiographic
tracings.
The serum CK level (normal range 24 to 195 IU/L) and,
after inhibition of the monomer with monoclonal anti-
body, the CK-MB catalytic activity (normal range 0 to 30
IU/L) were measured by standard methods by means of a
Hitachi 717 analyzer and reagents from Boehringer-
Mannheim (Mannheim, Germany). The serum cardiac
troponin T concentration (normal range 0 to 0.02 mg/L)
was analyzed by an enzyme immunoassay using reagents
and an ES300 analyzer from Boehringer-Mannheim. In
the present study, 0.02 mg/L was chosen as the upper value
of the normal range, although some investigators have
determined the limit to be 0.015 mg/L.10 Thus patients
with detectable circulating troponin T at a level greater
than 0.02 mg/L before the operation were compared with
those who had preoperative circulating levels of 0.02 mg/L
or less. In a study of 32 patients with chronic stable angina
treated medically with no intention to offer CABG in our
institution, troponin T serum levels averaged 0.012 6
0.013 mg/L.
The clinical diagnosis of congestive heart failure after
CABG was based on radiologic evidence or signs of
pulmonary venous congestion after stabilization of body
weight immediately after the operation and the use of
angiotensin-converting enzyme inhibitors to control the
patients’ clinical signs and symptoms.
Statistical analysis. Data were analyzed by Student’s t
test for continuous variables and by the x2 test for
Table I. Preoperative clinical, angiographic and
laboratory characteristics of 468 patients according









Age (yr) 64 6 9 61 6 10 0.004
Sex
Men 77 (78%) 311 (84%) 0.3
Women 20 (22%) 60 (16%)
Angina
Unstable 54 (57%) 148 (40%) 0.006
Stable 43 (43%) 223 (60%)
Classes III1IV 78 (79%) 264 (71%) 0.009
Classes I1II 19 (21%) 107 (29%)
Previous MI 69 (71%) 219 (59%) 0.02
History of CHF 17 (18%) 16 (4%) 0.00004
Left main stenosis 21 (22%) 78 (21%) 0.8
One-vessel disease 1 1
Two-vessel disease 25 101 0.6
Three-vessel disease 71 269
LV ejection fraction (%) 47 6 14 57 6 12 0.000001
Repeat CABG (n) 17 (18%) 49 (13%) 0.3
Total CK (IU/L)
(mean 6 SD)
71 6 49 63 6 51 0.2
CK-MB (IU/L)
(mean 6 SD)
9 6 10 7 6 7 0.1
Troponin T (mg/L)
(mean 6 SD)
0.33 6 0.91 0.005 6 0.007 0.00001
MI, Myocardial infarction; CHF, congestive heart failure; LV, left ventri-
cle; CABG, coronary artery bypass grafting; CK, creatine kinase.
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discontinuous variables. The Mann-Whitney U test and
the Kruskal-Wallis one-way analysis of variance were used
in the analyses of hospital stay. Logistic regression analy-
ses of the following variables usually related to cardiac
events after surgery were used to determine which vari-
ables correlated most strongly with MI and congestive
heart failure during the perioperative period: (1) age at
operation, (2) preoperative functional class, (3) previous
MI (between 1 and 4 weeks of CABG), (4) number of
coronary arteries diseased, (5) presence of left main
coronary artery disease, (6) left ventricular ejection frac-
tion, (7) previous CABG, and (8) stable/unstable angina.
Analyses were performed with the use of the NCSS 6.0
program (Kaysville, Utah). Data are complete for all
patients. Data are expressed as mean, standard deviation,
and 95% confidence interval.
Results
Preoperative profile of patients. Among the 468
patients included in the present study, 97 (21%) had
a serum troponin T level above the limit of 0.02
mg/L before elective CABG (group 1) and 371
(79%) patients had levels equal to or below 0.02
mg/L (group 2).
Patients with a troponin T serum level greater
than 0.02 mg/L before the operation (group 1) were
older and more likely to have unstable or severe
angina (class III-IV), congestive heart failure, or a
lower left ventricular ejection fraction than patients
with lower troponin T levels (group 2). Whereas the
serum level of troponin T was higher in group 1,
preoperative CK-MB serum levels were similar be-
tween the two groups (Table I).
Twenty-four patients of group 1 had an acute MI
15 6 2 days before CABG and 25 patients of group
2 had an acute MI 20 6 2 days before CABG (p 5
0.02). No difference was detected in preoperative
levels of troponin T between patients with and
without recent acute MI. In group 2, serum levels
averaged 0.005 6 0.006 mg/L (95% confidence in-
terval [CI]: 0.004 to 0.006, n 5 347) in patients
without recent acute MI and 0.008 6 0.007 mg/L
(95% CI: 0.004 to 0.010, n 5 24) in patients with
recent acute MI. In group 1, these values were
0.180 6 0.278 mg/L (95% CI: 0.115 to 0.244, n 5 74)
and 0.802 6 1.744 mg/L (95% CI: 0.048 to 1.556, n 5
23), respectively. Preoperative troponin T serum
levels averaged 0.022 6 0.07 mg/L (95% CI: 0.012 to
0.030, n 5 266) in patients with stable angina and
0.138 6 0.648 mg/L (95% CI: 0.049 to 0.228, n 5
202) in patients with unstable angina.
Operative data. Group 1 patients had a longer
CPB time for a similar operation and needed more
pharmacologic and mechanical support for weaning
from CPB than patients who had normal circulating
Table II. Operative data of 468 patients undergoing










Grafts per patient, mean 2.9 6 1 2.9 6 1 0.9
Complete revascularization 86 (89%) 315 (85%) 0.4
CPB time (min) 90 6 33 81 6 26 0.007
Crossclamp time (min) 53 6 19 49 6 17 0.07
Total volume of cardiople-
gia (ml)
1092 6 398 1025 6 432 0.2
Cardioplegia
Warm 48 (49%) 244 (65%) 0.004
Cold 49 (51%) 126 (35%)
Antegrade 66 (68%) 260 (70%) 0.6
Retrograde 31 (32%) 111 (30%)
Blood losses (ml)
Intraoperative 669 6 415 593 6 339 0.1
Postoperative 859 6 684 910 6 737 0.6
Weaning from bypass with
inotropic agents
23 (24%) 67 (18%) 0.2
Weaning from bypass with
vasopressors
44 (45%) 104 (28%) 0.002
Weaning from bypass with
IABP
7 (7%) 4 (1%) 0.0005
Cardiac index (L/min/m2)
Before CPB 2.23 6 0.47 2.38 6 1.88 0.4
After CPB 2.8 6 0.68 2.8 6 0.64 0.7
Spontaneous return to sinus
rhythm (No. of
patients)
69 (72%) 278 (75%) 0.5
Temporary cardiac pacing
(No. of patients)
9 (9%) 26 (7%) 0.4
CPB, Cardiopulmonary bypass; IABP, intraaortic balloon pump.
Table III. Postoperative morbidity, mortality, and
hospital length of stay of 468 patinets according to









Death, within 30 days 1 (1%) 3 (1%) 0.9
Myocardial infarction 9 (9%) 12 (3%) 0.015
Congestive heart failure 10 (10%) 8 (2%) 0.0009
Myocardial infarction or
congestive heart failure
18 (19%) 16 (4%) 0.0001
Cerebrovascular accident 1 (1%) 8 (2%) 0.7
Reexploration for
hemorrhage
1 (1%) 11 (3%) 0.5
Average length of stay (days)
Intensive care unit
(median)
6 6 9 (4.6) 4 6 3 (4) 0.0006
Hospital (median) 10 6 10 (7.5) 8 6 4 (7) 0.09
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troponin T levels in the preoperative period (Table
II). No significant difference was noted in the vol-
ume of cardioplegic solution infused nor in the
route of administration of cardioplegic solution
between the two groups, but group 2 patients had
warm blood cardioplegia more often. Cardiac index,
measured by the thermodilution method at the
beginning and at the end of the operation, showed
no difference between the two groups.
Postoperative morbidity and mortality. Although
there was no difference in hospital mortality (1% in
each), patients with higher preoperative serum lev-
els of troponin T were more likely to have a
perioperative MI (9% versus 3%), congestive heart
failure (10% versus 2%), and acute MI or congestive
heart failure (19% versus 4%) after CABG than
patients with normal levels. In the present study, 12
patients had a new Q wave with a significant in-
crease in CK-MB concentration after CABG and
nine patients had an increase in CK-MB release
associated with a positive pyrophosphate scan, es-
tablishing the diagnosis of perioperative MI.9
Lengths of stay in the intensive care unit and in the
hospital were longer in patients with high preoper-
ative troponin T levels (Table III).
Biochemical markers of myocardial damage and
necrosis. Group 1 patients had higher levels of the
cardiac-specific protein 1 to 48 hours after the
operation than did group 2 patients, in whom levels
of troponin T were within normal limits before the
operation (Fig. 1, p , 0.0001). Although CK-MB
serum levels were higher after surgery in the former
group, the difference was not statistically significant
(Fig. 2, p 5 0.7).
The correlation between circulating troponin T
levels in the preoperative period and the rate of MI
after the operation shows a significant increase in
cardiac events with increasing serum levels of the
cardiac-specific protein (Fig. 3, p 5 0.03). The
logistic regression analysis showed that the factors
most strongly correlated with perioperative MI were
the higher level of circulating troponin T before
surgery (x2 5 8.72, p 5 0.003) and reoperation for
CABG (x2 5 4.36, p 5 0.037). The other indepen-
dent variables were not significantly correlated with
perioperative MI.
The variable most strongly associated with post-
operative congestive heart failure and with any
cardiac events defined as MI or congestive heart
failure was the higher level of circulating troponin T
before the operation (x2 5 5.83, p 5 0.016, and x2 5
16.79, p 5 0.0001).
Discussion
Stratification of surgical risk. In the current era
of quality control and of health care delivery re-
forms, prediction of clinical outcomes after cardiac
surgical procedures has become a major issue for
specialty societies, government, and third-party pay-
Fig. 1. Group 1 patients had higher serum levels of
troponin T 1 to 48 hours after CABG than group 2 (p ,
0.0001). Group 1 patients had serum levels of troponin T
greater than 0.02 mg/L and group 2 patients had serum
levels of troponin T less than 0.02 mg/L in the preopera-
tive period. Mean 6 standard error.
Fig. 2. Group 1 patients had higher serum levels of
CK-MB 1 to 48 hours after CABG than group 2, but the
difference was not statistically significant. Group 1 pa-
tients had serum levels of troponin T greater than 0.02
mg/L and group 2 patients has serum levels of troponin T
less than or equal to 0.02 mg/L in the preoperative period.
Mean 6 standard error.
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ers.2, 3 The Society of Thoracic Surgeons’ national
database reported an average operative mortality of
2.27% for 126,107 patients who underwent elective
CABG in 1994.2 Tu and Naylor11 reported an
operative mortality of 1.9% after elective CABG in
9733 patients operated on between 1991 and 1993 in
the province of Ontario. In the present study, oper-
ative mortality averaged 1% even though most
patients had unstable or severe angina before the
operation, 99 patients had left main coronary artery
disease, and 71 had undergone previous CABG.
It appears that more sensitive end points than
hospital mortality should be used to monitor the
quality of care of patients undergoing elective
CABG. MI and congestive heart failure after CABG
are complications that reflect the overall quality of
the decision and intervention process from surgical
indication, coronary anatomy, grafting techniques,
choice of conduits, and methods of intraoperative
myocardial protection to postoperative care of pa-
tients. Although the definition and clinical signifi-
cance of perioperative MI and of congestive heart
failure after CABG remain controversial, most au-
thors recognize that perioperative MI has a negative
effect on long-term clinical results.13, 14 Moreover,
increase in CK-MB after transluminal coronary an-
gioplasty and after CABG is now recognized as a
significant adverse event with increased late cardiac
mortality.15, 16
The cardiac-specific troponin T protein. Tropo-
nin T is a new and specific marker of myocardial
ischemia and necrosis.5 This cardiac-specific protein
is located in the thin filament of the myocardial
contractile apparatus. The difference in amino acid
composition between cardiac and skeletal muscle
troponin T allows the differentiation of the two
molecules by immunologic technique. Thus the se-
rum level of troponin T is a useful and precise tool
for diagnosis of MI17, 18 and for assessment of
myocardial damage during cardiac surgery.7, 19
Moreover, troponin T has been used as an indepen-
dent marker of risk in patients with acute myocar-
dial ischemia, troponin T levels above 0.1 ng/ml at
the time of admission being associated with a higher
mortality within 30 days.20, 21
Troponin T is also found in a small free cytosolic
amount and in a larger structurally bound fraction of
myocardial cells.17 Transient leakage from the cyto-
solic pool through reversibly damaged cell mem-
branes was suggested to explain the low serum levels
of circulating troponin T in patients with unstable
angina compared with patients with high serum
values 3 to 5 days after MI.22
Preoperative stratification with troponin T. In
the present study, patients with serum levels above
0.02 mg/L before elective CABG were older, at
higher risk by clinical signs and symptoms, and had
a lower left ventricular ejection fraction than pa-
tients with lower or no trace of the cardiac-specific
protein. The number of cardiac events after surgery,
MI and congestive heart failure, was significantly
higher in the former group of patients. Nineteen
percent of patients with troponin T serum levels
higher than 0.02 mg/L and 23% of those with levels
above 0.1 mg/L before CABG had a perioperative
MI or a clinical episode of congestive heart failure
after the operation (Fig. 3).
Patients with an elevated serum level of troponin
T before the operation needed greater and longer
hospital care, as shown by the difference in the use
Fig. 3. The positive correlation between circulating tro-
ponin T levels before the operation and the rate of MI
after the operation (p 5 0.03), the rate of congestive heart
failure (CHF) (p 5 0.0006), and the rate of cardiac events
(MI 1 CHF) (p 5 0.0001) were significant. Group 2
comprised patients with troponin T levels below the
discriminator value of 0.02 mg/L. Group 1 comprised
patients with elevated troponin T value. They were di-
vided into two subgroups: troponin T value between 0.02
m/L and 0.1 mg/L and values above 0.1 mg/L.
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of vasopressor drugs, intraaortic balloon pumping,
and in the period of stay in the intensive care unit
and in the hospital. Postoperative troponin T and
CK-MB serum levels were also higher among pa-
tients with detected circulating cardiac-specific tro-
ponin T in the preoperative period, although the
difference for CK-MB levels did not reach statistical
significance.
The presence of circulating troponin T before
CABG suggests that myocardial microscopic necro-
sis or reversible damage to myocardial cells was
present despite optimal medical treatment, normal
electrocardiographic findings, and normal serum
CK-MB levels before the operation. Unrecognized
myocardial microscopic necrosis or reversible cell
injury may be responsible for the presence of circu-
lating troponin in patients with unstable angina and
in symptom-free patients.21 Detection of a signifi-
cant level of circulating troponin T before surgery
increased the risk of perioperative MI by 2.9, and
the risk of congestive heart failure after CABG by
4.8, compared with the risks in patients with little or
no trace of the cardiac-specific protein. Thus high
troponin T level before CABG identifies a subgroup
of patients at much higher risk of serious adverse
cardiac events after surgery, who require more
intense and longer care than patients without de-
tectable cardiac-specific protein.
A greater proportion of group 1 patients were
subjected to warm blood cardioplegia, a method
associated with lower postoperative release of se-
rum troponin T than cold blood cardioplegia.7 Yet
the enzyme release after the operation was signifi-
cantly higher in the latter group than in group 2
patients (see Fig. 1). This also suggests that better
methods of myocardial protection during CABG
remain to be developed.
The present study encompasses several limita-
tions. First, we combine the results of two clinical
trials performed between 1992 and 1995; second,
the threshold value for troponin T levels is lower
than the levels chosen by other authors.6 The latter
limitations could have induced misclassification of
some patients in the two groups and the former
explains the longer hospital stay observed in this
study compared with our current practice. Although
we excluded all patients with recent (,1 week)
acute MI, high levels of troponin T before CABG
could have been related to preoperative acute MI in
some patients. Because there was no difference in
preoperative troponin T levels between patients
with or without recent acute MI (,4 weeks from
CABG), we are confident that preoperative tropo-
nin T levels were not associated with recent acute
MI before CABG.
Clinical implications. Risk stratification before
cardiac surgery is currently performed by means of
sophisticated statistical models based on several
clinical signs, symptoms, and laboratory data in
large databases. This approach is of great value but
depends on the quality of definition and of collec-
tion of the data. Moreover, these models present
significant error and are not suitable for clinical use
at the bedside in a patient population with an
expected mortality rate close to 1%. Preoperative
troponin T serum level appears to identify a sub-
group of patients with unrecognized myocardial
necrosis or reversible myocardial cell injury, who are
at a greater risk of cardiac events after the operation
and who could benefit from improved methods of
anesthesia, myocardial protection, surgical revascu-
larization, and preoperative stabilization with med-
ical treatment.
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